nach oben

Erschienen in:

25.01.2016 | Original Article

Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia

verfasst von: Manon M. C. Komen, Wim P. M. Breed, Carolien H. Smorenburg, Tjeerd van der Ploeg, S. H. Goey, Jacobus J. M. van der Hoeven, Johan W. R. Nortier, Corina J. G. van den Hurk

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

For patients, chemotherapy-induced alopecia (CIA) is one of the most distressing side effects of treatment. Scalp cooling can prevent or minimise CIA; the results may depend on the duration of cooling. Since a previous study on post-infusion cooling time in patients treated with docetaxel chemotherapy found no difference between 90 and 45 min, we investigated whether hair-preserving results could be maintained with a shorter post-infusion cooling time.

Methods

In this prospective, multi-centre randomised study, 134 patients who started treatment with docetaxel 75–100 mg/m² in a 3-weekly schedule were randomly assigned in a 1:1 ratio to a post-infusion cooling time of 45 or 20 min. The primary end point was the need for a wig or other head covering as assessed by the patient. A visual analogue scale (VAS) with a range from 0 (not tolerable) to 10 (very tolerable) was used to measure tolerance.

Results

Scalp cooling results were similar for 45- and 20-min post-infusion cooling times. Thirty-three out of 45 patients (73 %) treated with 20 min of post-infusion cooling did not need a form of head covering, compared with 41 out of 52 patients (79 %) treated with 45 min of post-infusion cooling (p = 0.5). The procedure was well tolerated (mean visual analogue score 8.3). Six patients stopped due to intolerance during the first treatment cycle.

Conclusions

A 20-min post-infusion cooling time is effective and tolerable for patients treated with scalp cooling to prevent docetaxel-induced alopecia.

Trial registration

Trialregister.nl Identifier, NTR 1856.

Lemieux J, Maunsell E, Provencher L (2008) Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17:317–328CrossRefPubMed

Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP (2009) Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer 17:181–189CrossRefPubMed

Rosman S (2004) Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns 52:333–339CrossRefPubMed

van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP (2010) Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology 19:701–709CrossRefPubMed

Batchelor D (2001) Hair and cancer chemotherapy: consequences and nursing care—a literature study. Eur J Cancer Care (Engl) 10:147–163CrossRef

Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D (2004) Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 12:543–549PubMed

van den Hurk CJG, Winstanley J, Boyle F, Young A (2015) Measurement of chemotherapy-induced alopecia—time to change. Support Care Cancer 23:1197–1199CrossRefPubMed

Breed W, van den Hurk CJ, Peerbooms M (2011) Presentation, impact and prevention of chemotherapy induced hair loss: scalp cooling potentials and limitations. Dermatology 6:109–125

Bulow J, Friberg L, Gaardsting O, Hansen M (1985) Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man. Scand J Clin Lab Invest 45:505–508CrossRefPubMed

10.

Grevelman EG, Breed WP (2005) Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 16:352–358CrossRefPubMed

11.

Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW (2013) Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 18:885–891CrossRefPubMedPubMedCentral

12.

Lemenager M, Lecomte S, Bonneterre ME, Bessa E, Dauba J, Bonneterre J (1997) Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer 33:297–300CrossRefPubMed

13.

Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314–322PubMed

14.

Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13:2643–2655PubMed

15.

Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil GM, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez MR, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341–2354PubMed

16.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J (2010) Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 116:4227–4237CrossRefPubMed

17.

Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358–1365CrossRefPubMed

18.

Massey CS (2004) A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs 8:121–130CrossRefPubMed

19.

van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients—results of the Dutch Scalp Cooling Registry. Acta Oncol 51:497–504CrossRefPubMed

20.

Auvinen PK, Mahonen UA, Soininen KM, Paananen PK, Ranta-Koponen PH, Saavalainen IE, Johansson RT (2010) The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 96:271–275PubMed

21.

Betticher DC, Delmore G, Breitenstein U, Anchisi S, Zimmerli-Schwab B, Muller A, von Moos R, Hugli-Dayer AM, Schefer H, Bodenmann S, Buhler V, Trueb RR (2013) Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer 21:2565–2573CrossRefPubMed

22.

van den Hurk CJ, Breed WP, Nortier JW (2012) Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 20:3255–3260CrossRefPubMed

23.

World Health Organization (1979) WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva, p 45

24.

Christodoulou C, Klouvas G, Efstathiou E, Zervakis D, Papazachariou E, Plyta M, Skarlos DV (2002) Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology 62:97–102CrossRefPubMed

25.

Katsimbri P, Bamias A, Pavlidis N (2000) Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 36:766–771CrossRefPubMed

26.

Ridderheim M, Bjurberg M, Gustavsson A (2003) Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 11:371–377PubMed

27.

Peerbooms M, Breed WPM, van den Hurk CJG (2015) Familiarity, opinions, experiences and knowledge about scalp cooling—a Dutch survey among breast cancer patients and oncological professionals. Asia Pac J Oncol Nurs 2:35–41CrossRef

28.

Chamberlain AJ, Dawber RP (2003) Methods of evaluating hair growth. Australas J Dermatol 44:10–18CrossRefPubMed

29.

Van Neste D (1999) Human scalp hair growth and loss evaluation methods: is there simple and reliable method? Exp Dermatol 8:299–301PubMed

30.

Van Neste MD (2002) Assessment of hair loss: clinical relevance of hair growth evaluation methods. Clin Exp Dermatol 27:358–365CrossRefPubMed

31.

Cohen B (2008) The cross-section trichometer: a new device for measuring hair quantity, hair loss, and hair growth. Dermatol Surg 34:900–910PubMed

32.

Hendriks MA, Geerts PA, Dercksen MW, van den Hurk CJ, Breed WP (2012) Evaluation of Cohen’s cross-section trichometer for measuring hair quantity. Dermatol Surg 38:631–634CrossRefPubMed

33.

Hilton S, Hunt K, Emslie C, Salinas M, Ziebland S (2008) Have men been overlooked? A comparison of young men and women’s experiences of chemotherapy-induced alopecia. Psychooncology 17:577–583CrossRefPubMed

34.

Sweeney C, Chen Y-H, Carducci MA, Liu G (2014) Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32:5s (suppl; abstr LBA2)

35.

Van den Hurk CJG (2013) Safety and effectiveness of scalp cooling in cancer patients undergoing cytotoxic treatment. Doctoral thesis, Department of Clinical Oncology, Faculty of Medicine / Leiden University Medical Center (LUMC), Leiden University

Titel: Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia
verfasst von: Manon M. C. Komen
Wim P. M. Breed
Carolien H. Smorenburg
Tjeerd van der Ploeg
S. H. Goey
Jacobus J. M. van der Hoeven
Johan W. R. Nortier
Corina J. G. van den Hurk
Publikationsdatum: 25.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 6/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3084-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia